Poor glycaemic control is the major factor associated with increased frequency of gastrointestinal symptoms in patients with diabetes mellitus by Abid, Shahab et al.
eCommons@AKU
Department of Medicine Department of Medicine
January 2007
Poor glycaemic control is the major factor
associated with increased frequency of
gastrointestinal symptoms in patients with diabetes
mellitus
Shahab Abid
Aga Khan University, shahab.abid@aku.edu
Wasim Jafri
Aga Khan University, wasim.jafri@aku.edu
Firdous Jahan
Aga Khan University
Fauziah Rabbani
Aga Khan University, fauziah.rabbani@aku.edu
Najmul Islam
See next page for additional authors
Follow this and additional works at: https://ecommons.aku.edu/pakistan_fhs_mc_med_med
Part of the Internal Medicine Commons
Recommended Citation
Abid, S., Jafri, W., Jahan, F., Rabbani, F., Islam, N., Khan, M., Masood, R. (2007). Poor glycaemic control is the major factor associated
with increased frequency of gastrointestinal symptoms in patients with diabetes mellitus. Journal of Pakistan Medical Association, 57(7),
345-349.
Available at: https://ecommons.aku.edu/pakistan_fhs_mc_med_med/535
Authors
Shahab Abid, Wasim Jafri, Firdous Jahan, Fauziah Rabbani, Najmul Islam, Masood H. Khan, and Rana
Masood
This article is available at eCommons@AKU: https://ecommons.aku.edu/pakistan_fhs_mc_med_med/535
Original Article
Poor glycaemic control is the major factor associated with increased frequency of
gastrointestinal symptoms in patients with diabetes mellitus
Shahab Abid1, Amir Rizvi1, Firdous Jahan2, Fauziah Rabbani3, Najmul Islam1, Masood H. Khan4, Rana Masood4,
Wasim Jafri1
Departments of Medicine1, Family Medicine2 and Community Health Sciences, Aga Khan University, and Department of Medicine, Civil Hospital,
Karachi3, Pakistan.
Abstract
Objective: To compare the GI symptoms in diabetic patients with controls and its relationship with the
complications, duration of diabetes and glycaemic control. 
Methods: Consecutive patients were prospectively enrolled in to two groups. Group I (diabetic patients) and
Group II (non-diabetic, Controls). Patient's characteristics, demographic profiles and GI symptoms were
evaluated on a questionnaire. Groups were compared for differences in various GI symptoms. Group I was
further analyzed for the relationship between GI symptoms with complications, duration of diabetes and
glycaemic control.
Results: A total of 514 patients were enrolled 250 were diabetics (group I) and 264 were non-diabetics (group
II). Mean age was 51.8 + 10.6 years and 50.2 + 9.2 years in groups i and ii respectively. All GI symptoms;
heartburn, dyspepsia, bowel related abdominal pain, diarrhea, constipation, and faecal incontinence were
significantly more in diabetics than controls (P<. 05).
The presence of diabetic neuropathy, retinopathy and HbA1c of >7 were significantly (P <. 05) related to GI
symptoms. Duration of diabetes (>10 years) was not found significantly linked to GI symptoms.
Conclusions: GI symptoms in diabetics were more frequent then control subjects and were significantly
associated with poor glycaemic control, neuropathy and retinopathy but not with duration of diabetes.  Number
of GI symptoms increases with the severity of poor glycaemic control in diabetic patients (JPMA 57:345:2007). 
Introduction
GI symptoms are common in the general population,
particularly the symptoms of dyspepsia.1 Studies have
shown that GI symptoms are more frequent in diabetic
patients compared to non-diabetic controls but results are
still diverging.2 For instance, by using self administered,
mailed questionnaires, results obtained showed no
differences in the prevalence of GI symptoms when diabetic
patients were compared with controls.3 On the other hand in
a population based survey it was found that diabetes
mellitus is associated with an increased prevalence of upper
and lower GI symptoms.4 Moreover the link between
duration of diabetes and development of GI symptoms were
found to be confusing. A study done in the Chinese
population showed significant link between the duration of
diabetes and the frequency of GI symptoms5, while in
another study, duration of diabetes or type of treatment was
not found to be associated significantly with increased
frequency of GI symptoms in diabetics.4 Similarly the
pathogenesis of GI symptoms in diabetic patients remains
poorly defined. It has been suggested that symptoms reflect
abnormal GI motility as a manifestation of irreversible
autonomic neuropathy.6 However other factors are also
important e.g. acute changes in blood glucose, poor
glycemic control and fluctuation in insulin level7 and
associated infections notably Helicobacter pylori.8
The aim of this study was therefore to examine the
prevalence of GI symptoms in type II diabetic patients
treated at a diabetes clinic compared to control subjects. In
addition, the relationship between the duration of diabetes,
glycaemic control and complications of diabetes with the
prevalence of GI symptoms in diabetic patients was also
determined.
Patients and Methods
This prospective study was performed at out
patient's clinic of two major hospitals (Aga Khan University
Hospital, a private university hospital and Civil Hospital -
Karachi, a major hospital in public sector) from September
2002 to November 2003.  The diabetes clinics of these
hospitals cater to out-patients who seek care for their
diabetes control and for the management of diabetes related
complications. The patients in both hospitals are from
diverse socio-economic and ethnic backgrounds and hence
represent the general diabetic population at large. 
Study subjects were divided into two groups. Group
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I (diabetic patients) attending diabetes clinic and Group II
(non-diabetic, controls) who were randomly enrolled from
executive check-up clinic or pre-employment medical
examination and those who were attending medical
outpatients clinics for some other reason. The following
patients were excluded: (i) those with previous history or
newly documented organic GI lesion, including peptic ulcer
(diagnosed on endoscopy), biliary stones or other pathology
in biliary system, GI tract tumor, prior GI surgery,
scleroderma or other connective tissue diseases, anatomical
obstruction or stricture; (ii) those with impairment of
hepatic or renal function; (iii) those with other medical
disorders, e.g. heart failure, cerebro-vascular accident; (iv)
Type 1 diabetic patients, defined by an acute presentation
with ketoacidosis or heavy ketonuria (>3+ ) or starting
insulin within 1 year of diagnosis, and requiring insulin
continuously thereafter.9 All patients were evaluated by a
questionnaire10 which contained detailed information about
upper and lower abdominal symptoms within the last 12
months. All symptoms that are not completely self-
explanatory were anchored to a standard description. The
following eight GI symptoms groups were used for
screening. Unless stated otherwise, a symptom was counted
only if reported to occur more than 25% of the time over the
past 12 months. The questionnaire was filled by the patients
themselves with the assistance of non-medical staff blinded
for the diabetes status of the patient.
1. Gastroesophageal reflux symptoms-heartburn or acid 
regurgitation at least once a week. 
2. Dysmotility like Dyspepsia-epigastric pain or 
discomfort in combination with any upper dysmotility 
symptom (early satiety, postprandial fullness, bloating, 
abdominal swelling, nausea [at least two to three times 
a month], vomiting [at least once a month], and 
retching [at least once a month]). 
3. Ulcer like dyspepsia-localized epigastric pain or 
discomfort combined with at least two of the following 
characteristics: night pain, episodic pain, pain relieved 
by antacids, pain relieved by food or milk, pain 
provoked by being hungry. 
4. Bowel-related abdominal pain, abdominal pain or 
discomfort associated with at least two of three features 
(relieved with defecation, onset associated with a 
change in the frequency of stool, onset associated with 
a change in stool form). 
5. Diarrhoea-very loose or watery stools more than 75% 
of the time and no abdominal pain. 
6. Constipation-at least two of the following symptoms: 
<3-bowel movements/week, anal blockage, manual 
dis-impaction, lumpy or hard stools, incomplete 
evacuation, straining or patient taking fibers such as
bran, cereal or ispagulla husk daily to relive 
constipation.
7. Frequent abdominal pain-abdominal pain of at least 
moderate intensity occurring minimally once a week 
over the past 12 months. 
8. Faecal incontinence-leakage of bowel movements 
about once a month or more frequently.
The diabetic complications were classified as
present according to the following definitions: 
* Nephropathy: the patient answered yes to the question
"Did your doctor tell you about any kidney damage or
protein in your urine that is a result of your diabetes?" 
* Peripheral neuropathy: the patient answered yes to the
question "Do you suffer from 'pins and needles' in
your feet or hands?" 
* Retinopathy: the patient answered yes to the question
"Are you aware of any eye damage that is a result of
your diabetes?" and had received laser therapy.
Demographic profile, biochemical parameters,
duration of diabetes and HbA1c levels (last level available
at the time of filling the questionnaire), were also recorded. 
Statistical analysis was performed using SPSS
(version 11.5; SPSS, Chicago, IL). All results are expressed
as mean + SD. The analysis of covariance and chi-square
test were used for between group comparisons where
appropriate. Multivariate analysis was used to examine the
independent relationship between scoring for GI symptoms
and the following; duration of diabetes, presence of various
complications and HbA1c. A P-value <0.05 was considered
to be significant.
Institutional ethical committee's approval was
obtained from both study centers prior to the start of the
study. Informed consent was obtained from the patients
before filling the questionnaire.
Results
A total of 514 consecutive patients were enrolled
Group I (diabetic patients) had 250 (48.64%) and Group II
(non-diabetics- control) 264 (51.36%). Patients with
diabetes (Group I) were slightly older (mean age 51.8+
10.6 years) compared to non-diabetic patients (Group II,
mean age of 50.2 + 9.2 years). Both groups had
predominance of females. All eight-symptom groups were
reported more frequently in Group I compared to group II,
p< 0.05 (Table 1). 
A large proportion (44%) of patients had diabetes
more than 10 years and their mean HbA1c was 7.8%.
Neuropathy was present in 130 (52%); retinopathy in 102
(40.8%) and nephropathy in 14 (5.6%) patients with
diabetes.
Complications of diabetes such as peripheral
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neuropathy and retinopathy were significantly associated (p
< 0.05) with occurrence of one or more GI symptoms,
whereas nephropathy was not found to be associated with
increase frequency of GI symptoms among diabetic
patients. GI symptoms were present more frequently in
diabetic patients with HbA1c level of >7 (p=0.015).
However, duration of diabetes mellitus (more than 10 years)
was not found significantly associated with increased
frequency of GI symptoms. The relationship between
duration of diabetes and its complications with the presence
of GI symptoms are shown in Table 2.
Almost 75 percent of diabetic patients reported at
least one or more GI symptoms. All eight GI symptom-
groups were reported more frequently when the HbA1c
level was 7 or more. The frequency of gastro esophageal
reflux and dyspepsia was higher. More than half of diabetic
patients (52.8%) had two or more symptoms with HbA1c
level of > 7.9. The number of GI symptoms reported by 250
diabetic patients and the relationship with HbA1c level is
summarized in Table 3.
Discussion
It has been found that GI symptoms in diabetics are
associated with significant impact on the quality of life. In
one study11 up to 76% of patients attending diabetes clinic
had GI symptoms when specifically questioned. This study
also shows that all eight GI symptom groups were more
prevalent in diabetic individuals than controls. It was also
observed that the number of symptoms group increased
with the severity of poor glycaemic control in type II
diabetes.
Several studies have shown that acute changes in
blood glucose concentration have a major effect on motor
function throughout the GI tract in healthy subjects and in
patients with diabetes.12,13 Variations in blood glucose
concentration also have the potential to affect symptoms
arising from the GI tract.14 Studies have shown that the
perception of nausea, occurring as a result of proximal
gastric distention, is greater during hyperglycaemia.4 Acute
hyperglycaemia was found to be associated with delayed
gastric emptying in diabetics.15 It reduces lower esophageal
sphincter pressure and velocity of esophageal peristalsis and
alters motility of small intestine and gall bladder.16 Recently
it has been demonstrated that hyperglycaemia can trigger
transient lower esophageal relaxation and contribute to the
increased esophageal acid exposure in patients with
diabetes mellitus.7 Controversy still exists as some studies
showed a direct relationship between glycaemic control and
GI symptoms4,17 while others differ.5
Based on our observations, we believe that   acute or
sub-acute changes in glucose concentration (as reflected by
HbA1c levels) are a key factor associated with increased
frequency of GI symptoms. In our study it has been
observed that the upper GI symptoms were significantly
more in patients with glycated HbA1c of 7 or more. This
might be due to the direct effect of hyperglycaemia over the
vagus nerve, causing delayed gastric emptying, increased
degree of relaxation of proximal stomach or a central action
Table1. Patient's characteristics and Comparison of Gastrointestinal
symptoms between Group I (diabetics) and Group II (controls).
Patients characteristics and
Gastrointestinal Symptoms
Group I
(Diabetics)
N=250 (%)
Group II
(Controls)
N=264 (%)
P value
Age (mean ± SD)
Females (%)
Smokers (%)
Alcohol users (%)
Gastroesophageal reflux symptoms
Dysmotility like dyspepsia
Ulcer like Dyspepsia
Bowel related abdominal pain
Diarrhea
Constipation
Frequent abdominal pain
Fecal Incontinence
51.8 yrs ± 10.6
56
8
3
110 (44)
88 (35)
40 (16)
38 (15.2)
32 (12.8)
114 (45.8)
32 (12.8)
22 (8.8)
50.2 yrs ± 9.2
59.8
10
5
57 (21.6)
27 (10.2)
18 (6.8)
6 (2.2)
6 (2.2)
42 (15.9)
12 (4.5)
0
.001
<. 001
.05
.001
.007
<. 001
.03
<. 001
Table2: Relationship between duration and complications of diabetes
mellitus with Gastrointestinal symptoms.
Group I (Diabetic patients) GI symptoms (1 or >) P value
Present Absent
Diabetic Nephropathy n=14
Diabetic Neuropathy n=130
Diabetic Rretinopathy n=102
HbA1c < 7    n=74
HbA1c >=7   n=176
Duration of Diabetes < 10 yrs n=140
Duration of Diabetes  >10 yrs    n=110
8
106
86
44
142
102
84
6
24
16
30
34
38
26
NS*
.045
.035
NS*
.015
NS*
NS*
*NS = Non-significant. P >0.5
Table 3. Relationship between Number of Gastrointestinal symptoms
Reported and Glycated Hb (n=250).
Symptoms Patients (%) Mean HbAlc
0 symptom
1 symptom
2 symptoms
3 symptoms
4 symptoms
5 symptoms
6 symptoms
7 symptoms
64 (25.6)
54 (21.6)
54 (21.6)
30 (12)
28 (11.2)
10 (4)
10 (4)
0 (0)
7.3
7.5
8.5
7.9
8.4
8.6
8
-
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of hyperglycaemia over the brain vagal nuclei.  These
possible mechanisms suggest hyperglycaemia associated
significant increase in upper GI symptoms in diabetics.7
There are several other factors, which may be
responsible for increased GI symptoms in diabetics such as
autonomic neuropathy and concurrent infections. Despite its
significant negative impact on survival and quality of life,
diabetic autonomic neuropathy is among the least
recognized and understood complication of diabetes.
Several hypotheses concerning the multiple etiologies of
diabetic neuropathy include a metabolic insult to nerve
fibres, neurovascular insufficiency, autoimmune damage
and neuro-hormonal growth factor deficiency.
Hyperglycaemic activation of the polyol pathway leading to
accumulation of sorbitol and potential changes in the NAD:
NADH ratio may also cause direct neuronal damage. GI
manifestations of autonomic neuropathy are diverse and
symptoms and pathogenic mechanisms have been
categorized according to the specific part of the affected GI
tract.  Esophageal dysfunction results at least in part from
vagal neuropathy. Delayed gastric emptying largely
depends on vagus nerve function, which can be severely
disrupted in diabetes. Autoantibodies to autonomic nerves
have been demonstrated, associated with the development
of autonomic neuropathy in type 1 diabetics.18 Diarrhoea,
which is typically intermittent and faecal incontinence due
to poor sphincter tone, may be related to autonomic
neuropathy. The present study has shown a significant
association between diabetic neuropathy and retinopathy
and GI symptoms in diabetics.
Despite significant association of increase frequency
of GI symptoms in diabetics with neuropathy in our study,
we cannot conclude that neuropathy alone was responsible
for GI symptoms. This is because of the fact that no
association was found between duration of diabetes (that
usually correlates with the development of neuropathy) and
GI symptoms in our study. A large population based survey
concluded that neither poor glycaemic control nor
autonomic neuropathy alone is enough to explain the
pathogenesis of GI symptoms in all diabetic patients.4
However as evident from our study, poor gylcaemic control
plays an important role in generation of at least upper GI
symptoms in diabetics. 
Certain GI infections may also play an important
role in causation of GI symptoms; at least in a subset of
diabetic patients. It might be interesting to note that a high
prevalence of Helicobacter pylori was found among
diabetics compared to controls in a recently published study
associated with dyspeptic symptoms.8 Moreover concurrent
use of certain drugs may be important in causing GI
symptoms in diabetics. However a study has recently
reported that troublesome GI symptoms in patients with
diabetes do not appear to be caused by use of oral
hypoglycaemic medications or other drugs, except for
diarrhea which is strongly and independently associated
with metformin use.19
In summary, this study has provided further evidence
that both upper and lower GI symptoms were significantly
more common in type II diabetic patients compared to
controls. Poorer glycaemic control was associated with
significant increase in upper GI symptoms.  Moreover long-
term complications such as neuropathy and retinopathy
were found to be associated with increased frequency of GI
symptoms. However the duration of diabetes was not found
to be associated with increase in the frequency of GI
symptom in our study. 
It is therefore important that Gastroenterologists
start seeking support from other disciplines such as
dieticians, public health physicians and family medicine
practitioners. Attention should be directed towards health
promotion (e.g. smoking cessation and weight reduction)
and secondary diabetes prevention methods in order to
better manage diabetes and thus bring down case load
related to GI symptoms amongst diabetic patients.
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